{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:41:14Z","timestamp":1771609274359,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In the last twenty years, several studies have been conducted in the search for new therapeutic strategies in patients with food allergy; in particular, after the failure of injection immunotherapy, three different routes of administration, oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT), have been tested. The aim of this manuscript is to review OIT, SLIT, and EPIT clinical trials on food allergies and to suggest advantages and limits of the different routes of immunotherapy administration.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Main body<\/jats:title>\n<jats:p>Of the three different routes of immunotherapy used in the treatment of food allergy, OIT is, at present, the only one actually able to induce an increase in tolerance in the majority of patients. However, its use is affected by serious secondary effects, such as major abdominal symptoms and anaphylaxis. The combination with omalizumab reduces the percentage of serious side effects. There are not many studies with SLIT for food allergy, but they have nevertheless shown that it is possible to obtain an increase in tolerance; however, this increase is modest in comparison with that obtained by OIT. EPIT, performed through the diffusion of allergens on intact skin, is the most recent form of immunotherapy. Although there are many works on EPIT carried out in laboratory animals, only few clinical studies have been published in humans. EPIT, unlike OIT and SLIT, is not responsible for systemic secondary effects such as anaphylaxis and eosinophilic oesophagitis but only for local and mild effects in areas where the devices are applied. Moreover, EPIT is characterized by high patient adherence.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>OIT seems to have a prevalent application in patients who do not report previous symptoms of systemic or gastroenteric anaphylaxis, while SLIT and EPIT, in particular, could be more preferentially used in patients with a risk of anaphylaxis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-020-02466-x","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T09:03:02Z","timestamp":1596618182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic perspectives in food allergy"],"prefix":"10.1186","volume":"18","author":[{"given":"Francesco","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Argentiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Neglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"2466_CR1","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1542\/peds.2011-0204","volume":"128","author":"RS Gupta","year":"2011","unstructured":"Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128:e9\u201317.","journal-title":"Pediatrics"},{"key":"2466_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/all.12423","volume":"69","author":"BI Nwaru","year":"2014","unstructured":"Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69:992\u20131007.","journal-title":"Allergy"},{"key":"2466_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaci.2017.11.003","volume":"141","author":"SH Scherer","year":"2018","unstructured":"Scherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis prevention and management. J Allergy Clin Immunol. 2018;141:41\u201358.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2014.05.013","volume":"134","author":"HA Sampson","year":"2014","unstructured":"Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: a practice parameter update- 2014. J Allergy Clin Immunol. 2014;134:16\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/all.12262","volume":"68","author":"L Chad","year":"2013","unstructured":"Chad L, Ben-Shoshan M, Asai Y, Cherkaoui S, Alizadehfar R, St-Pierre Y, et al. A majority of parents of children with peanut allergy fear using the epinephrine auto-injector. Allergy. 2013;68:1605\u20139.","journal-title":"Allergy"},{"key":"2466_CR6","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1080\/21645515.2017.1359363","volume":"13","author":"M Chen","year":"2017","unstructured":"Chen M, Land M. The current state of food allergy therapeutics. Human Vacc Immunother. 2017;13:2434\u201342.","journal-title":"Human Vacc Immunother"},{"key":"2466_CR7","first-page":"52","volume":"45","author":"G Patriarca","year":"1998","unstructured":"Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: result of a standardizd protocol for oral desensitization. Hepato Gastroenterol. 1998;45:52\u20138.","journal-title":"Hepato Gastroenterol"},{"key":"2466_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/j.1398-9995.2004.00542.x","volume":"59","author":"P Meglio","year":"2004","unstructured":"Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow\u2019s milk allergy. Allergy. 2004;59:980\u20137.","journal-title":"Allergy"},{"key":"2466_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaci.2007.10.029","volume":"121","author":"G Longo","year":"2008","unstructured":"Longo G, Barbi E, Berti I, Menghetti R, Pittalis A, Ronfani L, et al. Specific oral tollerance induction in children with very severe cow\u2019s milk-induced reactions. J Allergy Clin Immunol. 2008;121:343\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2008.09.030","volume":"122","author":"JM Skripak","year":"2008","unstructured":"Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow\u2019s milk allergy. J Allergy Clin Immunol. 2008;122:1154\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2466_CR11","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1365-2222.2011.03749.x","volume":"41","author":"A Martorell","year":"2011","unstructured":"Martorell A, De la Hoz B, Ibanez MD, Bone J, Terrados MS, Michavila A, Plaza AM, Alonso E, Garde J, Nevot S, Echeverria L. Oral desensitization as a useful treatment in 2-year-old children with cow\u2019s milk allergy. Clin Exp Allergy. 2011;41(9):1297\u2013304.","journal-title":"Clin Exp Allergy"},{"key":"2466_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2011.10.023","volume":"129","author":"CA Keet","year":"2012","unstructured":"Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129:448\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2013.05.006","volume":"132","author":"CA Keet","year":"2013","unstructured":"Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow\u2019s milk allergy. J Allergy Clin Immunol. 2013;132:737\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaci.2009.05.022","volume":"124","author":"SM Jones","year":"2009","unstructured":"Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292\u2013300.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaci.2013.11.007","volume":"133","author":"BP Vickery","year":"2014","unstructured":"Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunothery. J Allergy Clin Immunol. 2014;133:468\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jaci.2014.11.005","volume":"135","author":"SD Narisety","year":"2015","unstructured":"Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135:1275\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","volume":"139","author":"BP Vickery","year":"2017","unstructured":"Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139:173\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"2466_CR18","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","volume":"379","author":"BP Vickery","year":"2018","unstructured":"AR101 oral immunotherapy for peanut allergy, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, et al. AR101 oral immunotherapy for peanut allergy. New Engl J Med. 2018;379(21):1991\u20132001.","journal-title":"New Engl J Med"},{"key":"2466_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2006.09.016","volume":"119","author":"AD Buchanan","year":"2007","unstructured":"Buchanan AD, Green TD, Jones SM, Scurloch AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphiylactic children with egg allergy. J Allergy Clin Immunol. 2007;119:199\u2013205.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.anai.2010.09.030","volume":"105","author":"BP Vickery","year":"2010","unstructured":"Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE- based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105:444\u201350.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2466_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1200435","volume":"367","author":"AW Burks","year":"2012","unstructured":"Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367:233\u201343.","journal-title":"N Engl J Med"},{"key":"2466_CR22","doi-asserted-by":"crossref","unstructured":"Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014; 10:1. Erratum in: Allergy Asthma Clin Immunol 2016;12:28.","DOI":"10.1186\/s13223-016-0133-1"},{"key":"2466_CR23","unstructured":"Rodriguez del Rio P, Diaz-Perales A, Sanchez-Garcia S, Escudero C, do Santos P, Catarino M, et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol. 2014;24: 240-248."},{"key":"2466_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jaci.2015.07.019","volume":"136","author":"S Sato","year":"2015","unstructured":"Sato S, Utsunomiya T, Imai T, Yanagida N, Asaumi T, Ogura K, et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol. 2015;136:1131\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/cea.13161","volume":"48","author":"A Abdel-Gadir","year":"2018","unstructured":"Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48:825\u201336.","journal-title":"Clin Exp Allergy"},{"key":"2466_CR26","first-page":"27","volume":"7","author":"S Andorf","year":"2019","unstructured":"Andorf S, Purington N, Kumar D, Long A, O\u2019Laughlin KL, Sicherer S, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. E Clin Med. 2019;7:27\u201338.","journal-title":"E Clin Med"},{"key":"2466_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/pai.12508","volume":"27","author":"RS Gruchalla","year":"2016","unstructured":"Gruchalla RS, Sampson HA, Liu AH, Shreffler W, Wallace PK, Togias A, et al. Effects of omalizumab on T lymphocyte function in inner-city children with asthma. Pediatr Allergy Immunol. 2016;27:328\u201331.","journal-title":"Pediatr Allergy Immunol"},{"key":"2466_CR28","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","volume":"132","author":"LC Schneider","year":"2013","unstructured":"Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132:1368\u201374.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR29","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","volume":"127","author":"KC Nadeau","year":"2011","unstructured":"Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow\u2019s milk allergy. J Allergy Clin Immunol. 2011;127:1622\u20134.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","volume":"137","author":"RA Wood","year":"2016","unstructured":"Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy. J Allergy Clin Immunol. 2016;137:1103\u201310.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","volume":"139","author":"AJ MacGinnitie","year":"2017","unstructured":"MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139:873\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2014.11.034","volume":"135","author":"MLK Tang","year":"2015","unstructured":"Tang MLK, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135:737\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","volume":"127","author":"EH Kim","year":"2011","unstructured":"Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127:640\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaci.2005.08.027","volume":"116","author":"E Enrique","year":"2005","unstructured":"Enrique E, Pineda F, Malek T, Bartra J, Basaga\u00f1a M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.jaci.2010.02.029","volume":"125","author":"C Dupont","year":"2010","unstructured":"Dupont C, Kalach N, Soulaines P, Legou\u00e9-Morillon S, Piloquet H, Benhamou PH. Cow\u2019s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125:1165\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR36","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jaci.2016.01.008","volume":"137","author":"SM Jones","year":"2016","unstructured":"Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137:1258\u201361.","journal-title":"J Allergy Clin Immunol"},{"issue":"1320\u20131326","key":"2466_CR37","first-page":"e1","volume":"144","author":"EH Kim","year":"2019","unstructured":"Kim EH, Yang L, Ye P, Guo R, Li Q, Kulis MD, Burks AW. Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2019;144(1320\u20131326):e1.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR38","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1001\/jama.2017.16591","volume":"318","author":"HA Sampson","year":"2017","unstructured":"Sampson HA, Shreffler EG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318:1798\u2013809.","journal-title":"JAMA"},{"key":"2466_CR39","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","volume":"139","author":"SM Jones","year":"2017","unstructured":"Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139:1242\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR40","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/cmi.2016.14","volume":"14","author":"V Dioszeghy","year":"2017","unstructured":"Dioszeghy V, Mondoulet L, Puteaux E, Dhelft V, Ligouis M, Plaquet C, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cell Mol Immunol. 2017;14:770\u201382.","journal-title":"Cell Mol Immunol"},{"key":"2466_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaci.2016.03.057","volume":"139","author":"L Tordesillas","year":"2017","unstructured":"Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP (+) regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189\u2013201.","journal-title":"J Allergy Clin Immunol"},{"key":"2466_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12967-018-1701-6","volume":"16","author":"S Esposito","year":"2018","unstructured":"Esposito S, Isidori C, Pacitto A, Salvatori C, Sensi L, Frati F, et al. Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature. J Transl Med. 2018;16:329.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02466-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:50Z","timestamp":1628121650000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02466-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2466"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02466-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"7 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}